Cargando…

IgE is associated with exacerbations and lung function decline in COPD

BACKGROUND: Both allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Lommatzsch, Marek, Speer, Timotheus, Herr, Christian, Jörres, Rudolf A., Watz, Henrik, Müller, Achim, Welte, Tobias, Vogelmeier, Claus F., Bals, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725269/
https://www.ncbi.nlm.nih.gov/pubmed/34983515
http://dx.doi.org/10.1186/s12931-021-01847-0
_version_ 1784626080478396416
author Lommatzsch, Marek
Speer, Timotheus
Herr, Christian
Jörres, Rudolf A.
Watz, Henrik
Müller, Achim
Welte, Tobias
Vogelmeier, Claus F.
Bals, Robert
author_facet Lommatzsch, Marek
Speer, Timotheus
Herr, Christian
Jörres, Rudolf A.
Watz, Henrik
Müller, Achim
Welte, Tobias
Vogelmeier, Claus F.
Bals, Robert
author_sort Lommatzsch, Marek
collection PubMed
description BACKGROUND: Both allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts. METHODS: COSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specific to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (≥ 100 IU/l) or normal in patients with COPD. RESULTS: Both in COSYCONET and WISDOM, total IgE was elevated (≥ 100 IU/l) in > 30% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and/or allergies. Men with at least one exacerbation in the last 12 months (50.6% of all men in COSYCONET) had higher median total IgE (71.3 IU/l) than men without exacerbations (48.3 IU/l): this difference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest tertiles of total IgE (> 91.5 IU/ml, adjusted OR: 1.62, 95% CI 1.12–2.34) or allergen-specific IgE (> 0.19 IU/ml, adjusted OR: 2.15, 95% CI 1.32–3.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy). CONCLUSION: These data suggest that IgE may play a role in specific COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01847-0.
format Online
Article
Text
id pubmed-8725269
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87252692022-01-06 IgE is associated with exacerbations and lung function decline in COPD Lommatzsch, Marek Speer, Timotheus Herr, Christian Jörres, Rudolf A. Watz, Henrik Müller, Achim Welte, Tobias Vogelmeier, Claus F. Bals, Robert Respir Res Research BACKGROUND: Both allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts. METHODS: COSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specific to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (≥ 100 IU/l) or normal in patients with COPD. RESULTS: Both in COSYCONET and WISDOM, total IgE was elevated (≥ 100 IU/l) in > 30% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and/or allergies. Men with at least one exacerbation in the last 12 months (50.6% of all men in COSYCONET) had higher median total IgE (71.3 IU/l) than men without exacerbations (48.3 IU/l): this difference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest tertiles of total IgE (> 91.5 IU/ml, adjusted OR: 1.62, 95% CI 1.12–2.34) or allergen-specific IgE (> 0.19 IU/ml, adjusted OR: 2.15, 95% CI 1.32–3.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy). CONCLUSION: These data suggest that IgE may play a role in specific COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01847-0. BioMed Central 2022-01-04 2022 /pmc/articles/PMC8725269/ /pubmed/34983515 http://dx.doi.org/10.1186/s12931-021-01847-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lommatzsch, Marek
Speer, Timotheus
Herr, Christian
Jörres, Rudolf A.
Watz, Henrik
Müller, Achim
Welte, Tobias
Vogelmeier, Claus F.
Bals, Robert
IgE is associated with exacerbations and lung function decline in COPD
title IgE is associated with exacerbations and lung function decline in COPD
title_full IgE is associated with exacerbations and lung function decline in COPD
title_fullStr IgE is associated with exacerbations and lung function decline in COPD
title_full_unstemmed IgE is associated with exacerbations and lung function decline in COPD
title_short IgE is associated with exacerbations and lung function decline in COPD
title_sort ige is associated with exacerbations and lung function decline in copd
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725269/
https://www.ncbi.nlm.nih.gov/pubmed/34983515
http://dx.doi.org/10.1186/s12931-021-01847-0
work_keys_str_mv AT lommatzschmarek igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT speertimotheus igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT herrchristian igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT jorresrudolfa igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT watzhenrik igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT mullerachim igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT weltetobias igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT vogelmeierclausf igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT balsrobert igeisassociatedwithexacerbationsandlungfunctiondeclineincopd
AT igeisassociatedwithexacerbationsandlungfunctiondeclineincopd